Cargando…

Could blocking the formation of amyloid channels rescue Alzheimer's phenotype?

In a most simplified way, we can say that much of the symptomatology that characterizes Alzheimer's disease (AD) can be attributed to a cascade of toxic events initiated by the presence in the interstitial space of the brain of oligomers of the β‐amyloid peptide (Aβ) peptide, a cleavage by‐prod...

Descripción completa

Detalles Bibliográficos
Autores principales: Guix, Francesc X, Dotti, Carlos G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760883/
https://www.ncbi.nlm.nih.gov/pubmed/29208637
http://dx.doi.org/10.15252/emmm.201708491
_version_ 1783291456793870336
author Guix, Francesc X
Dotti, Carlos G
author_facet Guix, Francesc X
Dotti, Carlos G
author_sort Guix, Francesc X
collection PubMed
description In a most simplified way, we can say that much of the symptomatology that characterizes Alzheimer's disease (AD) can be attributed to a cascade of toxic events initiated by the presence in the interstitial space of the brain of oligomers of the β‐amyloid peptide (Aβ) peptide, a cleavage by‐product of the Amyloid precursor protein (APP). Intuitively, it follows that the amyloid peptide is the ideal target to combat this disease. However, several anti‐Aβ therapies failed in clinical trials devoted to find a treatment for AD. However, last year, the results of a clinical trial prompted back the interests in this type of therapy. In this issue of EMBO Molecular Medicine, Martinez Hernandez and colleagues present encouraging results showing that the diphenylpyrazole compound Anle138b prevents and reduces the toxic effects of Aβ in a mouse model of AD (APPPS1ΔE9). Regarding the mechanisms of action, they present good evidence that Anle138b prevents the formation of conducting Aβ pores on artificial membranes and primary hippocampal neurons. While the data are encouraging, AD mouse models only represent part of the AD pathology and clinical trials are needed to determine the usefulness of Anle138b to treat AD patients.
format Online
Article
Text
id pubmed-5760883
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-57608832018-01-10 Could blocking the formation of amyloid channels rescue Alzheimer's phenotype? Guix, Francesc X Dotti, Carlos G EMBO Mol Med News & Views In a most simplified way, we can say that much of the symptomatology that characterizes Alzheimer's disease (AD) can be attributed to a cascade of toxic events initiated by the presence in the interstitial space of the brain of oligomers of the β‐amyloid peptide (Aβ) peptide, a cleavage by‐product of the Amyloid precursor protein (APP). Intuitively, it follows that the amyloid peptide is the ideal target to combat this disease. However, several anti‐Aβ therapies failed in clinical trials devoted to find a treatment for AD. However, last year, the results of a clinical trial prompted back the interests in this type of therapy. In this issue of EMBO Molecular Medicine, Martinez Hernandez and colleagues present encouraging results showing that the diphenylpyrazole compound Anle138b prevents and reduces the toxic effects of Aβ in a mouse model of AD (APPPS1ΔE9). Regarding the mechanisms of action, they present good evidence that Anle138b prevents the formation of conducting Aβ pores on artificial membranes and primary hippocampal neurons. While the data are encouraging, AD mouse models only represent part of the AD pathology and clinical trials are needed to determine the usefulness of Anle138b to treat AD patients. John Wiley and Sons Inc. 2017-12-05 2018-01 /pmc/articles/PMC5760883/ /pubmed/29208637 http://dx.doi.org/10.15252/emmm.201708491 Text en © 2017 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the Creative Commons Attribution 4.0 (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle News & Views
Guix, Francesc X
Dotti, Carlos G
Could blocking the formation of amyloid channels rescue Alzheimer's phenotype?
title Could blocking the formation of amyloid channels rescue Alzheimer's phenotype?
title_full Could blocking the formation of amyloid channels rescue Alzheimer's phenotype?
title_fullStr Could blocking the formation of amyloid channels rescue Alzheimer's phenotype?
title_full_unstemmed Could blocking the formation of amyloid channels rescue Alzheimer's phenotype?
title_short Could blocking the formation of amyloid channels rescue Alzheimer's phenotype?
title_sort could blocking the formation of amyloid channels rescue alzheimer's phenotype?
topic News & Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760883/
https://www.ncbi.nlm.nih.gov/pubmed/29208637
http://dx.doi.org/10.15252/emmm.201708491
work_keys_str_mv AT guixfrancescx couldblockingtheformationofamyloidchannelsrescuealzheimersphenotype
AT dotticarlosg couldblockingtheformationofamyloidchannelsrescuealzheimersphenotype